Navigation Links
QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
Date:9/4/2008

Pivotal Study Seeks to Enroll 750 Women at More Than 100 Sites in the U.S.

ANN ARBOR, Mich., Sept. 4 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, today announced that it has initiated a second Phase 3 clinical trial of Ophena(TM) (ospemifene tablets), the company's estrogen-free oral therapy in development for the treatment of vaginal symptoms associated with menopause.

The study is the second pivotal Phase 3 clinical trial for Ophena(TM), a new selective estrogen receptor modulator (SERM) for the treatment of postmenopausal vaginal syndrome (PVS), a common condition in postmenopausal women. PVS, also known as vaginal atrophy, is characterized by progressive long-term vaginal symptoms such as dryness, irritation and sexual pain (dyspareunia). The first Phase 3 trial for Ophena(TM) met all the co-primary endpoints at a 60 mg dosage, with statistically significant improvements in vaginal dryness and dyspareunia, as well as statistically significant improvement in the proportion of parabasal and superficial cells in the epithelium of vaginal walls and a decline in vaginal pH levels.

The randomized, double-blind study will seek to enroll 750 post-menopausal women at more than 100 trial centers throughout the United States. Women participating in the study will be treated with either a 60 mg once daily oral dose of Ophena(TM) or placebo over the 12-week treatment period. All women will also be supplied with a non-hormonal vaginal lubricant to be applied as needed during the treatment period.

The co-primary endpoints of the study are the change from baseline to week 12 in the percentage of parabasal cells in the vaginal maturation index, the percentage of superficial cells in the vaginal maturation index, vaginal pH, and improvements in the most bothersome moderate to severe vulvovaginal
'/>"/>

SOURCE QuatRx Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
2. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
3. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
4. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
5. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
6. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
7. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
8. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
9. Isis Initiates Clinical Trial of CRP Drug
10. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
11. Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company") today ... financial statements.  The Company recently changed its fiscal year ... application to list its common stock on a national ... DelMar,s financial statements as filed with the United States ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... Jan. 5, 2011 Although smoking is an expensive habit, ... quit smoking can seem like expensive purchases as well.  The ... try to do it "cold turkey" – the most popular ... to relapse.   The use of store brand ...
... Avaxia Biologics, Inc., a privately-held biotech company developing ... to the gastrointestinal tract, announced today that it ... of inflammatory bowel disease (IBD). Avaxia,s orally administered ... three different animal models and showed superior efficacy ...
Cached Medicine Technology:Resolved to Quit Smoking This Year? 2Resolved to Quit Smoking This Year? 3Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011 2
(Date:9/1/2014)... Developers of FCPX 3rd Party Products have announced ... Plugin from Pixel Film Studios. , “ProWorld has pushed the ... users now have the ability to create a 3D world ... Pixel Film Studios. “Blurring the line between professional and armature, ... turn a 2D HDRI image or Skybox Texture into a ...
(Date:9/1/2014)... 2014 Psychogenic Non-epileptic Seizures (PNES), also ... disorder that can have devastating effects on those who ... seizures however, they are not produced by electrical anomalies ... It is estimated that the numbers of persons suffering ... sclerosis. , Dr. Lorna Myers, Director of ...
(Date:8/31/2014)... An analysis of 32 studies compiled by ... link between lower levels of Vitamin D and a ... August 2014 issue of American Journal of Public ... Vitamin D found in blood. , Researchers found ... than 9 nanograms/milliliter (ng/mL) were twice as likely to ...
(Date:8/31/2014)... 2014 MedixSafe has become very popular ... and narcotics lockers . Electronic Security Specialists ... for distribution worldwide. “We have now shipped multiple orders ... MedixSafe Sales Manager , MedixSafe is a division of ... network cabling company with over 30 years in the ...
(Date:8/31/2014)... 2014 Just in time for Washington’s Indian ... wild, sustainable Alaska Salmon, award winning chowder and ... Duke's Green Lake location , Sunday, September 28, 2014 from ... several ethnic salmon BBQ culinary delights. Live music will add ... Hawaii, Puerto Rico and Mexico will be featured. “There ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released a New Tutorial Entitled ProWorld Lesson Exclusively for Final Cut Pro X 2Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 2Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 3Health News:Seattle Seafood Restaurant Duke's Chowder House on Green Lake Will Celebrate The Long Anticipated Indian Summer With First Annual Sizzling BBQ Salmon Tasting Event. 2
... took place even in prehistoric times. , , FRIDAY, June 13 ... based on the findings of a prehistoric mass grave in ... evidence from 34 skeletons dating back to around 5000 B.C. ... over the need for female companionship. , While adult ...
... June 13 EntreMed, Inc.,(Nasdaq: ENMD ... the treatment of cancer and inflammatory diseases,announced ... Chief Executive Officer,will present a Company overview ... Organization 2008 Annual International Convention,being held June ...
... trachomatis, the most ... Calif., June 13 Roche announced today that,its new ... Mark,certification, allowing it to be sold for clinical use ... target approach to help ensure,reliability of test results even ...
... terrorist attacks of September 11, 2001, had lasting psychological ... World Trade Center Health Registry, show that one in ... (PTSD) two to three years after the attacks. The ... three times the usual rate in the years following ...
... for Prevention, Mental,Health and Low-Income Programs, Boosted Quality ... Today a minority of,the U.S. Senate blocked critical ... million Americans who depend on it. The Medicare,Improvements ... improved,Medicare,s prevention, mental health, and low-income programs and,instituted ...
... Synovics,Pharmaceuticals, Inc., (OTC Bulletin Board: SYVC) a ... 2008, it formalized,a strategic partnership with Maneesh Pharmaceuticals, ... ("JV"). The JV between the,companies is intended to ... have access,to assets of Maneesh including personnel, drug ...
Cached Medicine News:Health News:Pursuit of Females Dates Way, Way Back 2Health News:EntreMed to Present at the BIO 2008 Annual International Convention 2Health News:New Roche Chlamydia Test Approved for Use in European Union 2Health News:New Roche Chlamydia Test Approved for Use in European Union 3Health News:1 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9/11 2Health News:AARP NY Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP NY Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 2Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 3Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 4Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 5Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 6
Binocular indirect ophthalmic lenses. Median field diagnosis & treatment....
Binocular indirect ophthalmic lenses. Ultra-High resolutions viewing of posterior pole....
... Volk's super series ... lenses. General retinal ... unprecedented fundus diagnostic ... maximum potential field ...
Volk indirect lenses. Standard BIO examinations....
Medicine Products: